Bacteria from Infectious Particles to Cell Based Anticancer Targeted Drug Delivery Systems

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2021 Dec 28

PMID 34959266

Citations 4

Authors

Mounir M Salem-Bekhit

Abdullah M E Youssof

Fars K Alanazi

Fadilah Sfouq Aleanizy

Alsuwyeh Abdulaziz

Ehab I Taha

Amro Abd Al Fattah Amara

Affiliations

Soon will be listed here.

Abstract

Bacterial ghosts (BGs) are empty cell envelopes of nonliving evacuated bacterial cells. They are free from their cytoplasmic contents; however, they sustain their cellular 3D morphology and antigenic structures, counting on bioadhesive properties. Lately, they have been tested as an advanced drug delivery system (DDS) for different materials like DNA, peptides, or drugs, either single components or combinations. Different studies have revealed that, BG DDS were paid the greatest attention in recent years. The current review explores the impact of BGs on the field of drug delivery and drug targeting. BGs have a varied area of applications, including vaccine and tumor therapy. Moreover, the use of BGs, their synthesis, their uniqueness as a delivery system and application principles in cancer are discussed. Furthermore, the safety issues of BGs and stability aspects of using ghost bacteria as delivery systems are discussed. Future perspective efforts that must be followed for this important system to continue to grow are important and promising.

Citing Articles

Cancer cell membrane-coated bacterial ghosts for highly efficient paclitaxel delivery against metastatic lung cancer.

Ling D, Jia X, Wang K, Yan Q, Yuan B, Du L Acta Pharm Sin B. 2024; 14(1):365-377.

PMID: 38261850 PMC: 10792973. DOI: 10.1016/j.apsb.2023.08.012.

Bacteria and Bacterial Components as Natural Bio-Nanocarriers for Drug and Gene Delivery Systems in Cancer Therapy.

Zong R, Ruan H, Liu C, Fan S, Li J Pharmaceutics. 2023; 15(10).

PMID: 37896250 PMC: 10610331. DOI: 10.3390/pharmaceutics15102490.

The potential use of bacteria and bacterial derivatives as drug delivery systems for viral infection.

Faghihkhorasani A, Ahmed H, Mashool N, Alwan M, Assefi M, Hussein Adab A Virol J. 2023; 20(1):222.

PMID: 37789431 PMC: 10548687. DOI: 10.1186/s12985-023-02183-z.

Bacteria associated with glioma: a next wave in cancer treatment.

Meng Y, Sun J, Zhang G, Yu T, Piao H Front Cell Infect Microbiol. 2023; 13:1164654.

PMID: 37201117 PMC: 10185885. DOI: 10.3389/fcimb.2023.1164654.

References

Marchart J, Dropmann G, Lechleitner S, Schlapp T, Wanner G, Szostak M . Pasteurella multocida- and Pasteurella haemolytica-ghosts: new vaccine candidates. Vaccine. 2003; 21(25-26):3988-97. DOI: 10.1016/s0264-410x(03)00383-9. View

Porter K, Raviprakash K . DNA Vaccine Delivery and Improved Immunogenicity. Curr Issues Mol Biol. 2016; 22:129-138. DOI: 10.21775/cimb.022.129. View

Huber B, Riedel K, Kothe M, Givskov M, Molin S, Eberl L . Genetic analysis of functions involved in the late stages of biofilm development in Burkholderia cepacia H111. Mol Microbiol. 2002; 46(2):411-26. DOI: 10.1046/j.1365-2958.2002.03182.x. View

Panthel K, Jechlinger W, Matis A, Rohde M, Szostak M, Lubitz W . Generation of Helicobacter pylori ghosts by PhiX protein E-mediated inactivation and their evaluation as vaccine candidates. Infect Immun. 2002; 71(1):109-16. PMC: 143412. DOI: 10.1128/IAI.71.1.109-116.2003. View

Huter V, Szostak M, Gampfer J, Prethaler S, Wanner G, Gabor F . Bacterial ghosts as drug carrier and targeting vehicles. J Control Release. 1999; 61(1-2):51-63. DOI: 10.1016/s0168-3659(99)00099-1. View

Langer R . Drug delivery and targeting. Nature. 1998; 392(6679 Suppl):5-10. View

Walcher P, Cui X, Arrow J, Scobie S, Molinia F, Cowan P . Bacterial ghosts as a delivery system for zona pellucida-2 fertility control vaccines for brushtail possums (Trichosurus vulpecula). Vaccine. 2008; 26(52):6832-8. DOI: 10.1016/j.vaccine.2008.09.088. View

A Ahmad T, Rammah S, Sheweita S, Haroun M, El-Sayed L . Development of immunization trials against Pasteurella multocida. Vaccine. 2013; 32(8):909-17. DOI: 10.1016/j.vaccine.2013.11.068. View

Youssof A, Salem-Bekhit M, Shakeel F, Alanazi F, Haq N . Analysis of anti-neoplastic drug in bacterial ghost matrix, w/o/w double nanoemulsion and w/o nanoemulsion by a validated 'green' liquid chromatographic method. Talanta. 2016; 154:292-8. DOI: 10.1016/j.talanta.2016.03.086. View

10.

Saleh N, Mahmoud H, Eltaher H, Helmy M, El-Khordagui L, Hussein A . Prodigiosin-Functionalized Probiotic Ghosts as a Bioinspired Combination Against Colorectal Cancer Cells. Probiotics Antimicrob Proteins. 2022; 15(5):1271-1286. PMC: 10491537. DOI: 10.1007/s12602-022-09980-y. View

11.

Panyam J, Labhasetwar V . Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev. 2003; 55(3):329-47. DOI: 10.1016/s0169-409x(02)00228-4. View

12.

Shams H . Recent developments in veterinary vaccinology. Vet J. 2005; 170(3):289-99. DOI: 10.1016/j.tvjl.2004.07.004. View

13.

Corbett D, Roberts I . The role of microbial polysaccharides in host-pathogen interaction. F1000 Biol Rep. 2010; 1:30. PMC: 2924690. DOI: 10.3410/B1-30. View

14.

Ebrahimi-Nik H, Bassami M, Mohri M, Rad M, Khan M . Bacterial ghost of avian pathogenic E. coli (APEC) serotype O78:K80 as a homologous vaccine against avian colibacillosis. PLoS One. 2018; 13(3):e0194888. PMC: 5864078. DOI: 10.1371/journal.pone.0194888. View

15.

Kim E, Won G, Lee J . Construction of a novel tetravalent dengue vaccine with a Salmonella Typhimurium bacterial ghost and evaluation of its immunogenicity and protective efficacy using a murine model. Vaccine. 2019; 38(4):916-924. DOI: 10.1016/j.vaccine.2019.10.075. View

16.

Groger M, Holnthoner W, Maurer D, Lechleitner S, Wolff K, Mayr B . Dermal microvascular endothelial cells express the 180-kDa macrophage mannose receptor in situ and in vitro. J Immunol. 2000; 165(10):5428-34. DOI: 10.4049/jimmunol.165.10.5428. View

17.

McBroom A, Johnson A, Vemulapalli S, Kuehn M . Outer membrane vesicle production by Escherichia coli is independent of membrane instability. J Bacteriol. 2006; 188(15):5385-92. PMC: 1540050. DOI: 10.1128/JB.00498-06. View

18.

Finbloom J, Sousa F, Stevens M, Desai T . Engineering the drug carrier biointerface to overcome biological barriers to drug delivery. Adv Drug Deliv Rev. 2020; 167:89-108. PMC: 10822675. DOI: 10.1016/j.addr.2020.06.007. View

19.

Zhang H, Chu W, Sun J, Liu Z, Huang W, Xue C . A novel autolysis system for extracellular production and direct immobilization of a phospholipase D fused with cellulose binding domain. BMC Biotechnol. 2019; 19(1):29. PMC: 6530184. DOI: 10.1186/s12896-019-0519-5. View

20.

Paukner S, Kohl G, Lubitz W . Bacterial ghosts as novel advanced drug delivery systems: antiproliferative activity of loaded doxorubicin in human Caco-2 cells. J Control Release. 2003; 94(1):63-74. DOI: 10.1016/j.jconrel.2003.09.010. View